Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 12/20 | 0.57 |
| ▸ | BCHE | P06276 | 11/20 | 0.55 |
| ▸ | MARK4 | Q96L34 | 1/20 | 0.55 |
| ▸ | FAAH | O00519 | 1/20 | 0.52 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mandelic Acid SCHEMBL2436177 | 1.00 | ACHE (0.57) | ACHEBCHEMARK4FAAHTRPM8 | |
| SCHEMBL6400603 | 0.84 | L3MBTL1 (0.58) | LMNAMAPK1 | |
| SCHEMBL503788 | 0.84 | L3MBTL1 (0.58) | LMNAMAPK1 | |
| SCHEMBL503789 | 0.84 | L3MBTL1 (0.58) | LMNAMAPK1 | |
| SCHEMBL2436055 | 0.84 | ACHE (0.61) | ACHEBCHEMARK4FAAHTRPM8 | |
| SCHEMBL2439189 | 0.84 | ACHE (0.61) | ACHEBCHEMARK4FAAHTRPM8 | |
| SCHEMBL2437370 | 0.84 | ACHE (0.61) | ACHEBCHEMARK4FAAHTRPM8 | |
| SCHEMBL30881618 | 0.84 | ACHE (0.61) | ACHEBCHEMARK4FAAHTRPM8 | |
| Mandelic Acid SCHEMBL2010439 | 0.83 | L3MBTL1 (0.52) | TRPM8LMNAMAPK1 | |
| SCHEMBL30441349 | 0.80 | TRPM8 (0.53) | ACHEBCHETRPM8TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255383-A1 | PREPARATION OF RIVASTIGMINE AND ITS SALTS | DR. REDDY'S LABORATORIES, INC. | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255383-A1 | PREPARATION OF RIVASTIGMINE AND ITS SALTS | ACHE, EHMT1, BCHE | ACHE 1/4885BCHE 3/4885MARK4 2635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.